Please login to the form below

Not currently logged in
Email:
Password:

GLP1 agonists

This page shows the latest GLP1 agonists news and features for those working in and with pharma, biotech and healthcare.

EMA: no new safety concerns with GLP-1 diabetes drugs

EMA: no new safety concerns with GLP-1 diabetes drugs

The GLP-1 based therapy class includes both glucagon-like-peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors.

Latest news

  • US charity calls for release of diabetes drug data US charity calls for release of diabetes drug data

    The concerned products comprise GLP-1 agonists, such as Byetta/Bydureon (exenatide) from Amylin/ Bristol Myers Squibb (BMS) and Victoza (liraglutide) from Novo Nordisk, as well as the DPP-4 inhibitors, ... data that reinforced "growing safety concerns"

  • Drug delivery

    Other deals of note were Boehringer Ingelheim's (BI) agreement with Zealand Pharma for rights to its ZP2929 - GLP1 receptor agonists against type 2 diabetes and obesity, further building the ... agonists (T2D and obesity). Development, Commercialisation

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...